Grifols and Alzheimer's
Since 2004, we have led a broad range of research initiatives on Alzheimer's as part of our commitment to making a difference to people living with this devastating disease.
Our Alzheimer's research began when we read a scientific article that posited that albumin, the most common protein in plasma, may have the ability to capture beta-amyloid, one of the proteins that builds up in the brains of Alzheimer's patients. We conducted a small clinical study aimed at proving the concept. This initial study paved the way for a second, larger study involving 42 patients in the U.S. and Spain. In 2013, the promising results of these early investigations led to a full-scale clinical trial that we called AMBAR: Alzheimer Management by Albumin Replacement.
The objective of the AMBAR clinical trial has been to evaluate the efficacy of plasma exchange – the extraction of plasma and its replacement with albumin – to slow the progression of Alzheimer's.
The study is our most ambitious clinical trial to date, but it is not our only line of investigation. Our commitment to alleviating the Alzheimer's epidemic is ongoing. We have researched AD from various perspectives over the last 15 years. We have invested more than €150 million (2004-2017) into Alzheimer's research, including innovative projects in early diagnosis and prevention vaccine, and new therapeutic possibilities for other age-related diseases. And we will continue our efforts, because innovation is the most powerful tool we have to improve the lives of patients.
It is currently estimated that 35 million people worldwide suffer from Alzheimer's, and this figure is continuing to grow.
The AMBAR hypothesis
AMBAR is an innovative treatment proposal aimed at slowing the progression of Alzheimer's disease through periodic plasma exchange.
AMBAR is an international and multicenter clinical trial designed by Grifols in collaboration with Fundació ACE in Barcelona, Spain; and the Alzheimer Disease Research Center in Pittsburgh, PA, U.S.